GeneBio and Insilicos Sign Global Distribution Agreement
Complete the form below to unlock access to ALL audio articles.
Geneva Bioinformatics (GeneBio) SA and Insilicos LLC have announced a partnership agreement that links GeneBio's Phenyx software platform for MS data analysis together with Insilicos' IPP (Insilicos Proteomics Pipeline), a proteomics pipeline, based on the TPP proteomics tools developed by Dr. Ruedi Aebersold's lab at the Institute for Systems Biology (ISB).
Under the terms of the agreement, Insilicos will be the exclusive global reseller of a bundled Phenyx/IPP offer, while GeneBio will be the exclusive European reseller of this Phenyx/IPP bundle.
In addition, GeneBio and Insilicos have acquired the right to non-exclusively sell each other's products in Europe and North America, respectively.
The technical aspect of the partnership involves the inclusion of Phenyx within the IPP, thereby allowing both IPP and TPP users to seamlessly utilize Phenyx within their specific workflows.
Phenyx is a software platform for the identification and characterization of proteins and peptides from mass spectrometry data specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic high quality results assessment.
IPP is a software system for the identification and analysis of proteomics data resulting from an open-source collaboration led by the ISB to further develop their TPP.
"We are delighted to have an opportunity to work with GeneBio and the Phenyx platform as it relates to our IPP," said Erik Nilsson, CEO of Insilicos.
"We realize that Phenyx is a powerful alternative to existing MS search engines and we want to give customers the best solutions available when it comes to implementing their IPP systems."
"We believe Phenyx is a unique platform offering a variety of features not found in other search engines, which is why we want the opportunity to resell the platform in North America. We believe this is the beginning of a prosperous relationship."
"We believe that the IPP is an important step forward for users of TPP and we want to insure that our Phenyx platform can be utilized seamlessly within the IPP workflow," said Nasri Nahas, CEO of GeneBio.
"Enabling IPP users to work closely with Phenyx will instantly expand the potential Phenyx user base, while at the same time allowing IPP users to experience the latest version of our powerful data analysis platform."
"We believe this TPP "booster" to be an important and welcomed enhancement and look forward to championing it throughout Europe. We are excited about the future possibilities of this relationship."
